S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
China Threat Triggers Potential Mining Boom for Investors (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
China Threat Triggers Potential Mining Boom for Investors (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
China Threat Triggers Potential Mining Boom for Investors (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Biden administration presses senators to avert rail strike
China Threat Triggers Potential Mining Boom for Investors (Ad)
Trump Org. defense lawyer scolded for using struck testimony
US stocks lose ground in uneven trading to open December
Copper Exploration Heating Up (Ad)
US employers added a strong 263,000 jobs in November in face of surging rate hikes by Fed
Closing prices for crude oil, gold and other commodities
LON:VAL

ValiRx - VAL Share Forecast, Price & News

GBX 15.48
-0.28 (-1.75%)
(As of 12/2/2022 01:23 PM ET)
Add
Compare
Today's Range
15.13
▼
15.85
50-Day Range
14.27
▼
18.79
52-Week Range
10
▼
44.50
Volume
739,180 shs
Average Volume
850,654 shs
Market Capitalization
£13.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VAL stock logo

About ValiRx (LON:VAL) Stock

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

VAL Stock News Headlines

November 10, 2022 | lse.co.uk
Suzy Dilly, ValiRx CEO reiterates her support for TheoremRx and hails 'brilliant science' Cytolytix
October 25, 2022 | lse.co.uk
ValiRx teams with King's College London for cancer project
October 25, 2022 | marketwatch.com
ValiRx Shares Rise on Subsidiary's Intellectual Property License Agreement
October 18, 2022 | finance.yahoo.com
Global Endometriosis Drugs Market to Reach $2.9 Billion by 2027 - Yahoo Finance
September 8, 2022 | lse.co.uk
UK announces 40 billion-pound liquidity plan for power firms | Financial News - London South East
September 8, 2022 | lse.co.uk
UK plans to hold a "fiscal event" this month | Financial News - London South East
September 8, 2022 | marketwatch.com
ValiRx Names Catherine Tralau-Stewart as Interim Chief Scientific Officer - MarketWatch
September 5, 2022 | ca.finance.yahoo.com
ValiRx plc (EAJF.F)
September 1, 2022 | morningstar.co.uk
EARNINGS UPDATES: Windward widens loss as operating expenses rise - Morningstar
August 31, 2022 | lse.co.uk
EARNINGS UPDATES: Windward widens loss as operating expenses rise
July 13, 2022 | lse.co.uk
IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress | Financial News - London South East
July 13, 2022 | marketwatch.com
ValiRx Shares Rise on Decision to Advance Breast-Cancer Treatment Program - MarketWatch
July 5, 2022 | morningstar.co.uk
IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option - Morningstar
June 30, 2022 | morningstar.co.uk
TRADING UPDATES: M&C Saatchi expects to deliver on annual profit - Morningstar
June 30, 2022 | morningstar.co.uk
LONDON BRIEFING: UK house market starts to slow but car output rises - Morningstar
June 30, 2022 | lse.co.uk
AIM WINNERS & LOSERS: Frasers invests in MySale; Kefi keeps license | Financial News - London South East
June 30, 2022 | morningstar.co.uk
AIM WINNERS & LOSERS: Frasers invests in MySale; Kefi keeps license - Morningstar
June 30, 2022 | marketwatch.com
ValiRx to Raise GBP1.5 Mln in Discounted Placing for Working Capital; Shares Fall - MarketWatch
June 18, 2022 | marketwatch.com
ValiRx Shares Fall on Potential Extension of Exclusivity Talks With TheoremRx - MarketWatch
June 17, 2022 | morningstar.co.uk
AIM WINNERS & LOSERS: M&C Saatchi pulls Next Fifteen deal support - Morningstar
June 17, 2022 | morningstar.co.uk
ValiRx shares drop as cancer drug sub-licensing progress stalls - Morningstar
June 7, 2022 | morningstar.co.uk
IN BRIEF: Literacy Capital sees uplifts across portfolio companies - Morningstar
June 7, 2022 | morningstar.co.uk
IN BRIEF: ValiRx widens annual loss as R&D costs climb - Morningstar
March 24, 2022 | lse.co.uk
Valirx News Headlines. VAL Share News. Financial News Articles for Valirx Plc Ord 0.1P updated throughout the day. - London South East
March 23, 2022 | morningstar.co.uk
TRADING UPDATES: Arecor Therapeutics wins patent... - Morningstar
See More Headlines
Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

VAL Company Calendar

Last Earnings
9/07/2020
Today
12/02/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:VAL
CUSIP
N/A
CIK
N/A
Web
www.valirx.com
Phone
+44-20-30084416
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1.77
Current Ratio
1.27
Quick Ratio
1.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
GBX 0.18 per share
Price / Cash Flow
86.11
Book Value
GBX 4.40 per share
Price / Book
3.52

Miscellaneous

Outstanding Shares
90,174,000
Free Float
N/A
Market Cap
£13.95 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Suzanne J. Dilly B.Sc. (Age 44)
    BSc, Ph.D., CEO & Director
    Comp: $159.18k
  • Mr. James Gerry Desler FCA (Age 66)
    CFO & Exec. Director
    Comp: $48k
  • Mr. Kumar Nawani
    Head of Operations
  • Dr. Catherine Jane Tralau-Stewart Ph.D.
    Chief Scientific Officer
  • Mr. Tarquin Edwards
    Head of Investor Relations & Communications
  • Mr. Mark Treharne
    Corp. Devel. Mang.

Key Competitors

View All Competitors













VAL Stock - Frequently Asked Questions

How have VAL shares performed in 2022?

ValiRx's stock was trading at GBX 36.25 at the start of the year. Since then, VAL shares have decreased by 56.6% and is now trading at GBX 15.75.
View the best growth stocks for 2022 here.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) released its quarterly earnings results on Monday, September, 7th. The company reported ($4.43) earnings per share for the quarter.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 15.75.

How much money does ValiRx make?

ValiRx (LON:VAL) has a market capitalization of £14.20 million.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The official website for the company is www.valirx.com. The company can be reached via phone at +44-20-30084416.

This page (LON:VAL) was last updated on 12/2/2022 by MarketBeat.com Staff